Evaxion AS
Company Profile
Business description
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Contact
Dr. Neergaards Vej 5f
Horsholm2970
DNKT: +45 31246427
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
46
Stocks News & Analysis
stocks
A closer look at US tech earnings
stocks
Cheap ASX energy share lifts earnings guidance on stronger output
stocks
ASX listed bank overvalued despite strong earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,909.60 | 42.50 | -0.47% |
| CAC 40 | 7,980.52 | 75.86 | -0.94% |
| DAX 40 | 24,040.32 | 309.96 | -1.27% |
| Dow JONES (US) | 49,399.59 | 304.88 | -0.61% |
| FTSE 100 | 10,221.62 | 47.81 | -0.47% |
| HKSE | 26,347.91 | 58.93 | -0.22% |
| NASDAQ | 26,168.16 | 105.96 | -0.40% |
| Nikkei 225 | 62,742.57 | 324.69 | 0.52% |
| NZX 50 Index | 13,080.33 | 130.15 | -0.99% |
| S&P 500 | 7,387.88 | 24.96 | -0.34% |
| S&P/ASX 200 | 8,670.70 | 40.60 | -0.47% |
| SSE Composite Index | 4,214.49 | 10.53 | -0.25% |